Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors
作者:Dingding Gao、Nan Jin、Yixian Fu、Yueyue Zhu、Yujie Wang、Ting Wang、Yuehong Chen、Mingming Zhang、Qiang Xiao、Min Huang、Yingxia Li
DOI:10.1016/j.ejmech.2021.113333
日期:2021.4
The cumulative evidence supports STAT3, a transcriptional mediator of oncogenic signaling, as a therapeutic target in cancer. The development of STAT3 inhibitors remain an active area of research as no inhibitors have yet to be approved for cancer treatment. In a continuing effort to develop more potent STAT3 inhibitors based on our previously identified hit compound 16w, a series of benzothiazole
累积的证据支持STAT3(一种致癌信号的转录介质)作为癌症的治疗靶标。STAT3抑制剂的开发仍然是一个活跃的研究领域,因为尚未批准任何抑制剂用于癌症治疗。在基于我们先前确定的命中化合物16w不断开发更有效的STAT3抑制剂的过程中,设计,合成和生物学评估了一系列在STAT3的SH2结构域具有独特结合模式的苯并噻唑衍生物。值得注意的是,化合物B19对IC 50表现出优异的针对IL-6 / STAT3信号通路的活性通过萤光素酶报告基因测定法测定的值低至0.067μM。此外,多种化合物显示出对MDA-MB-468和JAK2突变HEL细胞系有效的抗增殖活性。使用蛋白质印迹法的进一步生化研究表明,B19阻断了Tyr 705和Ser 727处STAT3的磷酸化,从而抑制了STAT3介导的c-MYC和MCL-1基因表达。同时,它在MDA-MB-468和HEL细胞系中诱导癌细胞G2 / M期阻滞和凋亡。最